ReviewTherapeutic advances in respiratory disease

Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.

Mario Malerba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.